Aardvark Therapeutics Aktie
Marktkapitalisierung
-
-
Streubesitz
32,28%
KGV
-
Index-Zuordnung
-
Aardvark Therapeutics, Inc. Common Stock Unternehmensprofil
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Vorstand
Dr. Tien-Li Lee M.D.
CEO, Sekretärin & Direktor
Herr Nelson B. Sun M.B.A.
CFO& COO
Dr. Manasi Sinha Jaiman M.D., M.P.H.
Leitender medizinischer Offizier
Dr. Timothy J. Kieffer Ph.D.
Wissenschaftlicher Leiter
Herr Christian Zapf J.D.
Chefsyndikus
Dr. Dvorit Samid Ph.D.
Geschäftsführender Vizepräsident für medizinische Angelegenheiten
Dr. Zhenhuan Zheng Ph.D.
Leiter der Forschungsabteilung
Herr Ron Lewis II, Ph.D.
VP & Leiter des CMC
Dr. Terrie Kellmeyer Ph.D.
Senior-Vizepräsident für regulatorische Angelegenheiten
Herr Justin T. Stege Ph.D.
VP und Leiter des Projektmanagements & Strategie
Aktionärsstruktur
58,967%
Institutionelle Aktionäre
49,796%
Freefloat
0%
Individuelle Aktionäre
Termine
Stammdaten
| Nennwert/Aktie | - |
| Land | USA |
| Währung | USD |
| Branche | Biotechnologie |
| Aktientyp | - |
| Sektor | Gesundheit |
| Gattung | - |
Quelle: Leeway